Eli Lilly is intensifying its legal efforts to combat the unauthorized sale of retatrutide, an experimental weight loss drug that has not yet received FDA approval. The pharmaceutical company has filed at least 11 federal lawsuits against online vendors and wellness clinics allegedly marketing and distributing unauthorized versions of the drug, often labeled as “research-use-only” products. Lilly is seeking to halt these sales, citing concerns over patient safety, product quality, and unfair competition. The litigation represents an expansion of the company’s broader enforcement strategy targeting unauthorized copies of its weight loss medications.
In an article with Bloomberg Law, Edgar J. Asebey highlighted the aggressive legal approach Lilly is taking against sellers of unapproved retatrutide products.
“They have very, very deep pockets and if they want to come after you, they will.”
He also emphasized the unusual circumstances surrounding the litigation, noting, “The particular mix here is novel because retatrutide is not even an approved drug and it’s already being knocked off.” His comments underscore the evolving legal and regulatory risks facing businesses involved in the marketing, distribution, and sale of experimental peptide products, particularly as pharmaceutical manufacturers pursue enforcement actions before their drugs reach the commercial market.
